Minor retinal degeneration in Parkinson's disease

Medical Hypotheses

Volumn 76, Issue 2, 2011, Pages 194-196

  Huang, Yan Ming ^a   Yin, Zheng Qin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL FUNCTION; CELL LOSS; CELLULAR DISTRIBUTION; DEAFFERENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; NONHUMAN; PARKINSON DISEASE; PHOTORECEPTOR CELL; RETINA DEGENERATION; SIGNAL TRANSDUCTION; VISION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DOPAMINE; HALLUCINATIONS; HAPLORHINI; HUMANS; MODELS, BIOLOGICAL; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; OXIDOPAMINE; PARKINSON DISEASE; QUAIL; RABBITS; RETINA; RETINAL DEGENERATION; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 78651094957     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.09.016     Document Type: Article

References (40)

1. de Rijk M.C., Breteler M.M., Graveland G.A., et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology 1995, 45:2143-2146.
2. Trenkwalder C., Schwarz J., Gebhard J., et al. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995, 52:1017-1022.
3. Nussbaum R.L., Ellis C.E. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003, 348:1356-1364.
4. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat 1988, 10:137-144.
5. Archibald N.K., Clarke M.P., Mosimann U.P., Burn D.J. The retina in Parkinson's disease. Brain 2009, 132:1128-1145.
6. Jones B.W., Marc R.E. Retinal remodeling during retinal degeneration. Exp Eye Res 2005, 81:123-137.
7. Witkovsky P., Schutte M. The organization of dopaminergic neurons in vertebrate retinas. Vis Neurosci 1991, 7:113-124.
8. Ammermuller J., Kolb H. The organization of the turtle inner retina. I. On- and off-center pathways. J Comp Neurol 1995, 358:1-34.
9. Witkovsky P., Nicholson C., Rice M.E., Bohmaker K., Meller E. Extracellular dopamine concentration in the retina of the clawed frog, Xenopus laevis. Proc Natl Acad Sci USA 1993, 90:5667-5671.
10. Nguyen-Legros J., Simon A., Caille I., Bloch B. Immunocytochemical localization of dopamine D1 receptors in the retina of mammals. Vis Neurosci 1997, 14:545-551.
11. Maguire G., Hamasaki D.I. The retinal dopamine network alters the adaptational properties of retinal ganglion cells in the cat. J Neurophysiol 1994, 72:730-741.
12. Mills S.L., Xia X.B., Hoshi H., et al. Dopaminergic modulation of tracer coupling in a ganglion-amacrine cell network. Vis Neurosci 2007, 24:593-608.
13. Skrandies W., Gottlob I. Alterations of visual contrast sensitivity in Parkinson's disease. Hum Neurobiol 1986, 5:255-259.
14. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol 2004, 108:17-40.
15. Lee J.Y., Djamgoz M.B. Retinal dopamine depletion in young quail mimics some of the effects of ageing on visual function. Vision Res 1997, 37:1103-1113.
16. Wong C., Ishibashi T., Tucker G., Hamasaki D. Responses of the pigmented rabbit retina to NMPTP, a chemical inducer of Parkinsonism. Exp Eye Res 1985, 40:509-519.
17. Tatton W.G., Kwan M.M., Verrier M.C., Seniuk N.A., Theriault E. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res 1990, 527:21-31.
18. Ghilardi M.F., Bodis-Wollner I., Onofrj M.C., Marx M.S., Glover A.A. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain 1988, 111(Pt 1):131-149.
19. Naarendorp F., Hitchock P.F., Sieving P.A. Dopaminergic modulation of rod pathway signals does not affect the scotopic ERG of cat at dark-adapted threshold. J Neurophysiol 1993, 70:1681-1691.
20. Domenici L., Trimarchi C., Piccolino M., Fiorentini A., Maffei L. Dopaminergic drugs improve human visual contrast sensitivity. Hum Neurobiol 1985, 4:195-197.
21. Gottlob I., Charlier J., Reinecke R.D. Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 1992, 33:2722-2728.
22. Jones R.D., Donaldson I.M., Timmings P.L. Impairment of high-contrast visual acuity in Parkinson's disease. Mov Disord 1992, 7:232-238.
23. Delalande I., Hache J.C., Forzy G., Bughin M., Benhadjali J., Destee A. Do visual-evoked potentials and spatiotemporal contrast sensitivity help to distinguish idiopathic Parkinson's disease and multiple system atrophy?. Mov Disord 1998, 13:446-452.
24. Langheinrich T., Tebartz van Elst L., Lagreze W.A., Bach M., Lucking C.H., Greenlee M.W. Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visually evoked potentials and psychophysics. Clin Neurophysiol 2000, 111:66-74.
25. Silva M.F., Faria P., Regateiro F.S., et al. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. Brain 2005, 128:2260-2271.
26. Pieri V., Diederich N.J., Raman R., Goetz C.G. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci 2000, 172:7-11.
27. Mosimann U.P., Mather G., Wesnes K.A., O'Brien J.T., Burn D.J., McKeith I.G. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004, 63:2091-2096.
28. Diederich N.J., Goetz C.G., Raman R., Pappert E.J., Leurgans S., Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998, 21:289-295.
29. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 1990, 13:296-302.
30. Kupersmith M.J., Shakin E., Siegel I.M., Lieberman A. Visual system abnormalities in patients with Parkinson's disease. Arch Neurol 1982, 39:284-286.
31. Buttner T., Kuhn W., Patzold T., Przuntek H. L-Dopa improves colour vision in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994, 7:13-19.
32. Sartucci F., Porciatti V. Visual-evoked potentials to onset of chromatic red-green and blue-yellow gratings in Parkinson's disease never treated with L-Dopa. J Clin Neurophysiol 2006, 23:431-435.
33. Stanzione P., Pierantozzi M., Semprini R., et al. Increasing doses of l-sulpiride reveal dose- and spatial frequency-dependent effects of D2 selective blockade in the human electroretinogram. Vision Res 1995, 35:2659-2664.
34. Harnois C., Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990, 31:2473-2475.
35. Inzelberg R., Ramirez J.A., Nisipeanu P., Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res 2004, 44:2793-2797.
36. Yazulla S., Studholme K.M. Volume transmission of dopamine may modulate light-adaptive plasticity of horizontal cell dendrites in the recovery phase following dopamine depletion in goldfish retina. Vis Neurosci 1995, 12:827-836.
37. Tucker G.S., Hamasaki D.I., Wong C.G. Intranuclear rodlets in the rabbit retina following treatment with MPTP. Exp Eye Res 1986, 42:569-583.
38. Dong C.J., Werblin F.S. Dopamine modulation of GABAC receptor function in an isolated retinal neuron. J Neurophysiol 1994, 71:1258-1260.
39. Djamgoz M.B., Hankins M.W., Hirano J., Archer S.N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 1997, 37:3509-3529.
40. Bodis-Wollner I. Visualizing the next steps in Parkinson disease. Arch Neurol 2002, 59:1233-1234.